Professor, Radiation Oncology, Emory University School of Medicine
Radiation Oncology
Dr. Ashesh B. Jani, MD
|
|
Give Review
Ashesh B. Jani is an expert in the field of Radiation Oncology. He researched medicine at University of Illinois College of Medicine. Ashesh Jani is a published doctor and has 101 publications published. The lastest was: 'Results of the 2014 Survey of the Association of Directors of Radiation Oncology Programs (ADROP).' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Prostate CT segmentation method based on nonrigid registration in ultrasound-guided CT-based HDR prostate brachytherapy.
- Video-based educational tool improves patient comprehension of common prostate health terminology.
- Reproducibility and Reliability of Anti-3-[(18)F]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an...
- Anti-3-[(18)F]FACBC Positron Emission Tomography-Computerized Tomography and (111)In-Capromab Pendetide Single Photon Emission Computerized Tomography-Computerized Tom...
- Influence of vascular comorbidities and race on erectile dysfunction after prostate cancer radiotherapy.
- The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of th...
- Severe lack of comprehension of common prostate health terms among low-income inner-city men.
- Treatment efficiency of volumetric modulated arc therapy in comparison with intensity-modulated radiotherapy in the treatment of prostate cancer.
- Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk.
- Feasibility of accelerated partial breast irradiation in a large inner-city public hospital.
- High-Dose Radiotherapy With or Without Androgen Deprivation Therapy for Intermediate-Risk Prostate Cancer: Cancer Control and Toxicity Outcomes.
- Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy f...
- Toxicity analysis of dose escalation from 75.6 gy to 81.0 gy in prostate cancer.
- A surveillance, epidemiology, and end results registry analysis of prostate cancer modality time trends by age.
- Stage IV prostate cancer: survival differences in clinical T4, nodal and metastatic disease.
- External Beam Radiotherapy for Prostate Cancer: Urinary Outcomes for Men with High International Prostate Symptom Scores (IPSS).
- External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity.
- Extensive inguinal lymphadenectomy improves overall 5-year survival in penile cancer patients: results from the Surveillance, Epidemiology, and End Results program.
- A review of low-dose-rate prostate brachytherapy--techniques and outcomes.
- Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
- Late rectal toxicity after prostate brachytherapy: influence of supplemental external beam radiation on dose-volume histogram analysis.
- Prostate cancer modality time trend analyses from 1973 to 2004: a Surveillance, Epidemiology, and End Results registry analysis.
- The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy.
- External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?
- Lymphadenectomy for patients with cervical cancer: is it of value?
- PET lesion segmentation using automated iso-intensity contouring in head and neck cancer.
- Influence of demographic factors on outcome of collecting duct carcinoma: a Surveillance, Epidemiology, and End Results (SEER) database analysis.
- Pelvic shape and prostate motion: implications for target volume design and analysis of acute toxicity.
- Case study of anti-1-amino-3-F-18 fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) to guide prostate cancer radiotherapy target design.
- Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
- International collaborations in radiation oncology: a single-institution experience in academic outreach.
- Salvage radiotherapy after postprostatectomy biochemical failure: does pretreatment radioimmunoscintigraphy help select patients with locally confined disease?
- Age and grade trends in prostate cancer (1974-2003): a Surveillance, Epidemiology, and End Results Registry analysis.
- Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulat...
- Early prostate cancer: hedonic prices model of provider-patient interactions and decisions.
- Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis.
- Integration of databases for radiotherapy outcomes analyses.
- Applying population dynamics modeling to patients with lymph node positive prostate cancer.
- Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
- The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.
- Chronic genitourinary and gastrointestinal toxicity of prostate cancer patients undergoing pelvic radiotherapy with intensity-modulated versus 4-field technique.
- Prostate cancer and race.
- Race and disparities in health.
- Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer.
- Quantitative evaluation of a cone-beam computed tomography-planning computed tomography deformable image registration method for adaptive radiation therapy.
- Role of external beam radiotherapy with low-dose-rate brachytherapy in treatment of prostate cancer.
- Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique.
- Postprostatectomy target-normal structure overlap volume differences using computed tomography and radioimmunoscintigraphy images for radiotherapy treatment planning.
- Intensity-modulated radiotherapy for neoadjuvant treatment of gastric cancer.
- Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity.
- Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
- Recent developments in nuclear medicine in the management of bone metastases: a review and perspective.
- Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
- Analysis of impact of age and race on biochemical control after radiotherapy in different prostate cancer settings.
- Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer.
- Opacity transfer function optimization for volume-rendered computed tomography images of the prostate.
- Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
- Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis.
- Analysis of acute toxicity with use of transabdominal ultrasonography for prostate positioning during intensity-modulated radiotherapy.
- Impact on late toxicity of using transabdominal ultrasound for prostate cancer patients treated with intensity modulated radiotherapy.
- A case study of radiotherapy planning for a bilateral metal hip prosthesis prostate cancer patient.
- Accuracy and reliability of the endoscopic classification of chronic radiation-induced proctopathy using a novel grading method.
- Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis.
- Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control.
- Analysis of prostate-specific antigen rebound interval in patients with prostate cancer receiving hormonal therapy and external-beam radiation therapy.
- Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
- Influence of radioimmunoscintigraphy on postprostatectomy radiotherapy treatment decision making.
- Impact of radioimmunoscintigraphy on definition of clinical target volume for radiotherapy after prostatectomy.
- Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans.
- The application of number needed to treat (NNT) to clinical problems in radiotherapy.
- Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
- Intensity-modulated radiation therapy for prostate cancer.
- Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer.
- Organ motion and IMRT in prostate cancer therapy.
- Oral vitamin a therapy for a patient with a severely symptomatic postradiation anal ulceration: report of a case.
- Selecting a secondary treatment.
- Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis.
- Dosimetric quality endpoints for low-dose-rate prostate brachytherapy using biological effective dose (BED) vs. conventional dose.
- Results of the 2014 Survey of the Association of Directors of Radiation Oncology Programs (ADROP).
- Early prostate cancer: clinical decision-making.
- A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemoth...
- American Radium Society 92nd Annual Meeting.
- Performance evaluation of Calypso 4D localization and kilovoltage image guidance systems for interfraction motion management of prostate patients.
- Boost first, eliminate systematic error, and individualize CTV to PTV margin when treating lymph nodes in high-risk prostate cancer.
- Role of androgen ablation with low-dose-rate brachytherapy in the treatment of prostate cancer.
- A critical review of variables affecting the accuracy and false-negative rate of sentinel node biopsy procedures in early breast cancer.
- Management strategies for locally advanced prostate cancer.
- An electronic application for rapidly calculating Charlson comorbidity score.
- Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for p...
- The effectiveness of combining hormone therapy and radiotherapy in the treatment of prostate cancer.
- Is there an association between multiple myeloma and prostate cancer?
- A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy.
- Increased mortality among Hispanic testis cancer patients independent of neighborhood socioeconomic status: a SEER study.
- Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer.
- PSA-based outcome analysis after radiation therapy for prostate cancer: a new definition of biochemical failure after intervention.
- Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience.
- Analysis of the role of adjuvant chemotherapy for invasive carcinoma of the esophagus.
- Volumetric visualization of head and neck CT data for treatment planning.
- Volume rendering quantification algorithm for reconstruction of CT volume-rendered structures: Part I. Cerebral arteriovenous malformations.
- Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques.
Schools
University of Illinois At Chicago College of Medicine
Rush Presbyn
University of Chicago
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Education
-
University of Chicago -
Rush University Medical Center -
University of Illinois College of Medicine
Hospital
-
Emory University Hospital -
Grady Memorial Hospital -
Emory University Hospital Midtown
Drug Facts
| NPI NUMBER | 1346280575 | |
| NPPES Provider LastName | JANI | |
| NPPES Provider FirstName | ASHESH | |
| NPPES Provider ZIPCode | 303221013 | |
| NPPES Provider State | GA | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 28.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346280575 |
| Last Name Of The Provider | JANI |
| First Name Of The Provider | ASHESH |
| View All |
Similar Doctors
|
|
Dr. Mylin A. Torres, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin A. Higgins, MD |
|
|
Dr. Brian W. Weaver, MD |
|
|
Dr. Hasan H. Danish, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaymin P. Jhaveri, MD |
|
|
Dr. Hui-Kuo Shu, MD |